{"transactions":[{"id":683543,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Performance Stock Units","published_at":"2026-08-18T20:05:08.000Z","date":"2026-08-15","kind":"grant","planned":false,"acquired":true,"shares":193575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents performance-based restricted stock units (\"PSUs\") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a conditional right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":440485,"derivative":{"underlying":"Common Stock","underlying_shares":193575},"source":{"system":"sec-edgar","filing":"0001673528-26-000017","document":"form4-08182026_040802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000017/form4-08182026_040802.xml","form_type":"4"}},{"id":693047,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Performance Stock Units","published_at":"2026-08-07T21:12:19.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":53334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents performance-based restricted stock units (\"PSUs\") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a conditional right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":53334,"derivative":{"underlying":"Common Stock","underlying_shares":53334},"source":{"system":"sec-edgar","filing":"0001673528-26-000016","document":"form4-08072026_090814.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000016/form4-08072026_090814.xml","form_type":"4"}},{"id":695713,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Performance Stock Units","published_at":"2026-08-05T22:24:55.000Z","date":"2026-08-02","kind":"grant","planned":false,"acquired":true,"shares":193576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents performance-based restricted stock units (\"PSUs\") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 2, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a conditional right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":387156,"derivative":{"underlying":"Common Stock","underlying_shares":193576},"source":{"system":"sec-edgar","filing":"0001673528-26-000014","document":"form4-08052026_100851.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000014/form4-08052026_100851.xml","form_type":"4"}},{"id":779182,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-14T20:05:11.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":271100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In addition to the options to purchase a total of 271,100 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 1,035,941 shares of common stock, which options vest according to their terms."}],"balance_after":271100,"derivative":{"exercise_price":17.81,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":271100},"source":{"system":"sec-edgar","filing":"0001673528-26-000013","document":"form4-05142026_040507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000013/form4-05142026_040507.xml","form_type":"4"}},{"id":779181,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-05-14T20:05:11.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":100200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":100200,"derivative":{"underlying":"Common Stock","underlying_shares":100200},"source":{"system":"sec-edgar","filing":"0001673528-26-000013","document":"form4-05142026_040507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000013/form4-05142026_040507.xml","form_type":"4"}},{"id":801876,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-23T22:07:34.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":31.12,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001673528-26-000012","document":"form4a-04232026_100429.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000012/form4a-04232026_100429.xml","form_type":"4/A","original_submission_date":"2026-04-22"}},{"id":802830,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":133400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":133400,"derivative":{"exercise_price":32.17,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":133400},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802829,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":133400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":133400,"derivative":{"exercise_price":43.91,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":133400},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802828,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":305500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":305500,"derivative":{"exercise_price":10.87,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":305500},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802827,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":305500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":305500,"derivative":{"exercise_price":14.83,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":305500},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802826,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":379620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":379620,"derivative":{"exercise_price":15.53,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":379620},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802825,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":379620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":379620,"derivative":{"exercise_price":21.19,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":379620},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802824,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":194900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":194900,"derivative":{"exercise_price":17.02,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":194900},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802823,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":194900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":194900,"derivative":{"exercise_price":23.23,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":194900},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802822,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":9200,"derivative":{"exercise_price":22.31,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802821,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":9200,"derivative":{"exercise_price":30.44,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802820,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":2321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":2321,"derivative":{"exercise_price":22.8,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":2321},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802819,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":2321,"derivative":{"exercise_price":31.12,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":2321},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802818,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":22.8,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802817,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T22:33:30.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":31.12,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001673528-26-000011","document":"form4-04222026_100425.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000011/form4-04222026_100425.xml","form_type":"4"}},{"id":802815,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":98600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F9","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit (\"RSU\") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":98600,"derivative":{"underlying":"Common Stock","underlying_shares":98600},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802814,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":80512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F9","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit (\"RSU\") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":80512,"derivative":{"underlying":"Common Stock","underlying_shares":80512},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802813,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":69355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F9","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit (\"RSU\") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":69355,"derivative":{"underlying":"Common Stock","underlying_shares":69355},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802812,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":17850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F9","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit (\"RSU\") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":17850,"derivative":{"underlying":"Common Stock","underlying_shares":17850},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802811,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":133400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":133400,"derivative":{"exercise_price":11.75,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":133400},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802810,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":305500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":305500,"derivative":{"exercise_price":3.97,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":305500},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802809,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":379620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":379620,"derivative":{"exercise_price":5.67,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":379620},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802808,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":194900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":194900,"derivative":{"exercise_price":6.22,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":194900},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802807,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":9200,"derivative":{"exercise_price":8.14,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802806,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":2321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":2321,"derivative":{"exercise_price":8.33,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":2321},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":802805,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-22T20:05:11.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":11000,"derivative":{"exercise_price":8.33,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001673528-26-000010","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000010/form4-04222026_040401.xml","form_type":"4"}},{"id":826362,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":100,"price":65.99,"value":6599.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":495965,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826361,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":3038,"price":65.1982,"value":198072.1316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.785 to $65.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":496065,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826360,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":3155,"price":64.1909,"value":202522.2895,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.71 to $64.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":499103,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826359,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":2592,"price":63.3503,"value":164203.9776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to $63.685 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":502258,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826358,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":1012,"price":62.1525,"value":62898.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":504850,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826357,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":550,"price":60.6264,"value":33344.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.405 to $61.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":505862,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826356,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":490,"price":59.6237,"value":29215.613,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.29 to $60.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":506412,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826355,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":3662,"price":58.6158,"value":214651.0596,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.29 to $59.275 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":506902,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826354,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":2570,"price":57.9063,"value":148819.191,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.29 to $58.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":510564,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826353,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":510,"price":56.613,"value":28872.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.285 to $57.215 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":513134,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":826352,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-03-28T00:15:44.000Z","date":"2026-03-25","kind":"grant","planned":false,"acquired":true,"shares":34300,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance-based restricted stock units (\"PSUs\") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 25, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each PSU represents a conditional right to receive one share of the Issuer's Common Stock."}],"balance_after":513644,"source":{"system":"sec-edgar","filing":"0001673528-26-000007","document":"form4-03282026_120340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000007/form4-03282026_120340.xml","form_type":"4"}},{"id":942120,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-10T00:12:18.000Z","date":"2026-01-07","kind":"exercise","planned":false,"acquired":false,"shares":26838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":80512,"derivative":{"underlying":"Common Stock","underlying_shares":26838},"source":{"system":"sec-edgar","filing":"0001673528-26-000006","document":"form4-01102026_120114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000006/form4-01102026_120114.xml","form_type":"4"}},{"id":942119,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-01-10T00:12:18.000Z","date":"2026-01-08","kind":"sale","planned":false,"acquired":false,"shares":14281,"price":44.71,"value":638503.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":479344,"source":{"system":"sec-edgar","filing":"0001673528-26-000006","document":"form4-01102026_120114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000006/form4-01102026_120114.xml","form_type":"4"}},{"id":942118,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-01-10T00:12:18.000Z","date":"2026-01-07","kind":"exercise","planned":false,"acquired":true,"shares":26838,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":493625,"source":{"system":"sec-edgar","filing":"0001673528-26-000006","document":"form4-01102026_120114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000006/form4-01102026_120114.xml","form_type":"4"}},{"id":943228,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T21:10:16.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":133400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":133400,"derivative":{"exercise_price":43.91,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":133400},"source":{"system":"sec-edgar","filing":"0001673528-26-000004","document":"form4-01082026_090111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000004/form4-01082026_090111.xml","form_type":"4"}},{"id":943227,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-08T21:10:16.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":98600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":98600,"derivative":{"underlying":"Common Stock","underlying_shares":98600},"source":{"system":"sec-edgar","filing":"0001673528-26-000004","document":"form4-01082026_090111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000004/form4-01082026_090111.xml","form_type":"4"}},{"id":943226,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-08T21:10:16.000Z","date":"2026-01-06","kind":"exercise","planned":false,"acquired":false,"shares":17850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":17850,"derivative":{"underlying":"Common Stock","underlying_shares":17850},"source":{"system":"sec-edgar","filing":"0001673528-26-000004","document":"form4-01082026_090111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000004/form4-01082026_090111.xml","form_type":"4"}},{"id":943225,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-01-08T21:10:16.000Z","date":"2026-01-07","kind":"sale","planned":false,"acquired":false,"shares":9202,"price":45.11,"value":415102.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":466787,"source":{"system":"sec-edgar","filing":"0001673528-26-000004","document":"form4-01082026_090111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000004/form4-01082026_090111.xml","form_type":"4"}},{"id":943224,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-01-08T21:10:16.000Z","date":"2026-01-06","kind":"exercise","planned":false,"acquired":true,"shares":17850,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":475989,"source":{"system":"sec-edgar","filing":"0001673528-26-000004","document":"form4-01082026_090111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000004/form4-01082026_090111.xml","form_type":"4"}},{"id":946759,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-01-07T02:07:28.000Z","date":"2026-01-03","kind":"exercise","planned":false,"acquired":false,"shares":34677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":69355,"derivative":{"underlying":"Common Stock","underlying_shares":34677},"source":{"system":"sec-edgar","filing":"0001673528-26-000002","document":"form4-01072026_020125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000002/form4-01072026_020125.xml","form_type":"4"}},{"id":946758,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-01-07T02:07:28.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":15309,"price":43.26,"value":662267.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":458139,"source":{"system":"sec-edgar","filing":"0001673528-26-000002","document":"form4-01072026_020125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000002/form4-01072026_020125.xml","form_type":"4"}},{"id":946757,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2026-01-07T02:07:28.000Z","date":"2026-01-03","kind":"exercise","planned":false,"acquired":true,"shares":34677,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the acquisition of 2,305 shares acquired under the Company's ESPP."}],"balance_after":473448,"source":{"system":"sec-edgar","filing":"0001673528-26-000002","document":"form4-01072026_020125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000167352826000002/form4-01072026_020125.xml","form_type":"4"}},{"id":1308073,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T22:27:26.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":305500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":305500,"derivative":{"exercise_price":14.83,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":305500},"source":{"system":"sec-edgar","filing":"0001415889-25-001034","document":"form4-01072025_100123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588925001034/form4-01072025_100123.xml","form_type":"4"}},{"id":1308072,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:27:26.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":107350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":107350,"derivative":{"underlying":"Common Stock","underlying_shares":107350},"source":{"system":"sec-edgar","filing":"0001415889-25-001034","document":"form4-01072025_100123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588925001034/form4-01072025_100123.xml","form_type":"4"}},{"id":1308071,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:27:26.000Z","date":"2025-01-06","kind":"exercise","planned":false,"acquired":false,"shares":17850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":35700,"derivative":{"underlying":"Common Stock","underlying_shares":17850},"source":{"system":"sec-edgar","filing":"0001415889-25-001034","document":"form4-01072025_100123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588925001034/form4-01072025_100123.xml","form_type":"4"}},{"id":1308070,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:27:26.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":false,"shares":34678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":104032,"derivative":{"underlying":"Common Stock","underlying_shares":34678},"source":{"system":"sec-edgar","filing":"0001415889-25-001034","document":"form4-01072025_100123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588925001034/form4-01072025_100123.xml","form_type":"4"}},{"id":1308069,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2025-01-07T22:27:26.000Z","date":"2025-01-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":6387,"price":15.3,"value":97721.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation."},{"field":"shares","element":"transactionShares","label":"F4","text":"The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes."}],"balance_after":436466,"source":{"system":"sec-edgar","filing":"0001415889-25-001034","document":"form4-01072025_100123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588925001034/form4-01072025_100123.xml","form_type":"4"}},{"id":1308068,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2025-01-07T22:27:26.000Z","date":"2025-01-06","kind":"exercise","planned":false,"acquired":true,"shares":17850,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":442853,"source":{"system":"sec-edgar","filing":"0001415889-25-001034","document":"form4-01072025_100123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588925001034/form4-01072025_100123.xml","form_type":"4"}},{"id":1308067,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2025-01-07T22:27:26.000Z","date":"2025-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":13033,"price":14.6,"value":190281.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation."},{"field":"shares","element":"transactionShares","label":"F4","text":"The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes."}],"balance_after":425003,"source":{"system":"sec-edgar","filing":"0001415889-25-001034","document":"form4-01072025_100123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588925001034/form4-01072025_100123.xml","form_type":"4"}},{"id":1308066,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2025-01-07T22:27:26.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":true,"shares":34678,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the acquisition of 212 shares acquired under the Company's ESPP."}],"balance_after":438036,"source":{"system":"sec-edgar","filing":"0001415889-25-001034","document":"form4-01072025_100123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588925001034/form4-01072025_100123.xml","form_type":"4"}},{"id":1449373,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-07-24T20:15:47.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics (\"Performance Metrics\"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026.  An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics (\"Performance Metrics\"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026.  An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date."}],"balance_after":160000,"derivative":{"underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001415889-24-020039","document":"form4-07242024_080744.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588924020039/form4-07242024_080744.xml","form_type":"4"}},{"id":1560584,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-27T00:10:20.000Z","date":"2024-03-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":347441,"price":21.6,"value":7504725.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation."}],"balance_after":401646,"source":{"system":"sec-edgar","filing":"0001415889-24-009164","document":"form4-03272024_120311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588924009164/form4-03272024_120311.xml","form_type":"4"}},{"id":1560583,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-27T00:10:20.000Z","date":"2024-03-25","kind":"sale","planned":false,"acquired":false,"shares":3000,"price":21.4225,"value":64267.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover a portion of the tax withholding obligations in connection with the vesting and settlement of RSUs.  The sales were to satisfy tax withholding obligations to be funded by \"sell to cover transactions\" and do not represent discretionary transactions by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes."}],"balance_after":749087,"source":{"system":"sec-edgar","filing":"0001415889-24-009164","document":"form4-03272024_120311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588924009164/form4-03272024_120311.xml","form_type":"4"}},{"id":1560582,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-27T00:10:20.000Z","date":"2024-03-22","kind":"sale","planned":false,"acquired":false,"shares":145940,"price":22.7846,"value":3325184.524,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Reporting Person to cover a portion of the tax withholding obligations in connection with the vesting and settlement of RSUs.  The sales were to satisfy tax withholding obligations to be funded by \"sell to cover transactions\" and do not represent discretionary transactions by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes."}],"balance_after":752087,"source":{"system":"sec-edgar","filing":"0001415889-24-009164","document":"form4-03272024_120311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000141588924009164/form4-03272024_120311.xml","form_type":"4"}},{"id":1682723,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-01-10T00:05:32.000Z","date":"2024-01-06","kind":"exercise","planned":false,"acquired":false,"shares":17850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":53550,"derivative":{"underlying":"Common Stock","underlying_shares":17850},"source":{"system":"sec-edgar","filing":"0001209191-24-001277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919124001277/doc4.xml","form_type":"4"}},{"id":1682722,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-01-10T00:05:32.000Z","date":"2024-01-08","kind":"sale","planned":false,"acquired":false,"shares":6866,"price":21.81,"value":149747.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":898027,"source":{"system":"sec-edgar","filing":"0001209191-24-001277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919124001277/doc4.xml","form_type":"4"}},{"id":1682721,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-01-10T00:05:32.000Z","date":"2024-01-06","kind":"exercise","planned":false,"acquired":true,"shares":17850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":904893,"source":{"system":"sec-edgar","filing":"0001209191-24-001277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919124001277/doc4.xml","form_type":"4"}},{"id":1685506,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-01-05T21:52:15.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":138710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":138710,"derivative":{"underlying":"Common Stock","underlying_shares":138710},"source":{"system":"sec-edgar","filing":"0001209191-24-001044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919124001044/doc4.xml","form_type":"4"}},{"id":1685505,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:52:15.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":379620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":379620,"derivative":{"exercise_price":21.19,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":379620},"source":{"system":"sec-edgar","filing":"0001209191-24-001044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919124001044/doc4.xml","form_type":"4"}},{"id":2057523,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-01-11T00:04:47.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":71400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":71400,"derivative":{"underlying":"Common Stock","underlying_shares":71400},"source":{"system":"sec-edgar","filing":"0001209191-23-002877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919123002877/doc4.xml","form_type":"4"}},{"id":2057522,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-11T00:04:47.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":194900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":194900,"derivative":{"exercise_price":23.23,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":194900},"source":{"system":"sec-edgar","filing":"0001209191-23-002877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919123002877/doc4.xml","form_type":"4"}},{"id":2320060,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2022-03-23T20:48:01.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":887043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the restricted stock units are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":887043,"source":{"system":"sec-edgar","filing":"0001209191-22-020792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919122020792/doc4.xml","form_type":"4"}},{"id":2398046,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-14T21:43:03.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":9200,"derivative":{"exercise_price":30.44,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001209191-22-009320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919122009320/doc4.xml","form_type":"4"}},{"id":2492091,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-30T22:26:09.000Z","date":"2021-11-26","kind":"grant","acquired":true,"shares":2321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in full on February 10, 2022, subject to the reporting person's continuous status as a director through February 10, 2022."}],"balance_after":2321,"derivative":{"exercise_price":31.12,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":2321},"source":{"system":"sec-edgar","filing":"0001209191-21-067159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919121067159/doc4.xml","form_type":"4"}},{"id":2492090,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-30T22:26:09.000Z","date":"2021-11-26","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total shares subject to the option shall vest on December 26, 2021 and 1/36th of the total shares subject to the option shall vest on each monthly anniversary thereafter, subject to the reporting person's continuous status as a director through each such date."}],"balance_after":11000,"derivative":{"exercise_price":31.12,"expiration_date":"2031-11-25","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-21-067159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000120919121067159/doc4.xml","form_type":"4"}},{"id":2881945,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2021-02-03T22:09:12.000Z","date":"2021-02-02","kind":"exercise","acquired":false,"shares":1340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested."}],"balance_after":63630,"derivative":{"exercise_price":114.33,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":1340},"source":{"system":"sec-edgar","filing":"0001214659-21-001205","document":"marketforms-51351.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465921001205/marketforms-51351.xml","form_type":"4"}},{"id":2881944,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-02-03T22:09:12.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":1340,"price":194.38,"value":260469.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020."}],"balance_after":30638,"source":{"system":"sec-edgar","filing":"0001214659-21-001205","document":"marketforms-51351.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465921001205/marketforms-51351.xml","form_type":"4"}},{"id":2881943,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-02-03T22:09:12.000Z","date":"2021-02-02","kind":"exercise","acquired":true,"shares":1340,"price":114.33,"value":153202.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020."}],"balance_after":31978,"source":{"system":"sec-edgar","filing":"0001214659-21-001205","document":"marketforms-51351.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465921001205/marketforms-51351.xml","form_type":"4"}},{"id":2902386,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-01-20T23:14:24.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":10979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested."}],"balance_after":10979,"derivative":{"exercise_price":214.47,"expiration_date":"2031-01-14","underlying":"Common Stock","underlying_shares":10979},"source":{"system":"sec-edgar","filing":"0001214659-21-000673","document":"marketforms-50973.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465921000673/marketforms-50973.xml","form_type":"4"}},{"id":2902385,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-20T23:14:24.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":7023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 25% annually on the anniversary of the grant date until fully vested."}],"balance_after":30638,"source":{"system":"sec-edgar","filing":"0001214659-21-000673","document":"marketforms-50973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465921000673/marketforms-50973.xml","form_type":"4"}},{"id":2912240,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-09T00:15:09.000Z","date":"2021-01-07","kind":"sale","acquired":false,"shares":2613,"price":216.33,"value":565270.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020."}],"balance_after":23615,"source":{"system":"sec-edgar","filing":"0001214659-21-000333","document":"marketforms-50910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465921000333/marketforms-50910.xml","form_type":"4"}},{"id":2912239,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-09T00:15:09.000Z","date":"2021-01-07","kind":"sale","acquired":false,"shares":12,"price":215.307,"value":2583.684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020."}],"balance_after":26228,"source":{"system":"sec-edgar","filing":"0001214659-21-000333","document":"marketforms-50910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465921000333/marketforms-50910.xml","form_type":"4"}},{"id":3315280,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-01-09T02:07:07.000Z","date":"2020-01-06","kind":"grant","acquired":true,"shares":64970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested."}],"balance_after":64970,"derivative":{"exercise_price":114.33,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":64970},"source":{"system":"sec-edgar","filing":"0001214659-20-000227","document":"marketforms-47394.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465920000227/marketforms-47394.xml","form_type":"4"}},{"id":3315279,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-01-09T02:07:07.000Z","date":"2020-01-06","kind":"grant","acquired":true,"shares":26240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 25% annually on the anniversary of the grant date until fully vested."}],"balance_after":26240,"source":{"system":"sec-edgar","filing":"0001214659-20-000227","document":"marketforms-47394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000121465920000227/marketforms-47394.xml","form_type":"4"}},{"id":3339118,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2019-12-17T21:42:23.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings)."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0000899243-19-029433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319029433/doc4.xml","form_type":"4"}},{"id":3339117,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:42:23.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":37.62,"expiration_date":"2026-05-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-029433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319029433/doc4.xml","form_type":"4"}},{"id":3339116,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:42:23.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":56.17,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000899243-19-029433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319029433/doc4.xml","form_type":"4"}},{"id":3339115,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:42:23.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":50.55,"expiration_date":"2028-01-17","underlying":"Common Stock","underlying_shares":26250},"source":{"system":"sec-edgar","filing":"0000899243-19-029433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319029433/doc4.xml","form_type":"4"}},{"id":3339114,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:42:23.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":42.73,"expiration_date":"2029-01-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-19-029433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319029433/doc4.xml","form_type":"4"}},{"id":3339113,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-12-17T21:42:23.000Z","date":"2019-12-17","kind":"other","acquired":false,"shares":38828,"price":114.5,"value":4445806.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. (\"Spark\"), Roche Holdings, Inc. (\"Roche\") and 022019 Merger Subsidiary, Inc. (\"Merger Sub\") (the \"Merger Agreement\" and the transactions contemplated thereby, the \"Merger\"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-029433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319029433/doc4.xml","form_type":"4"}},{"id":3576581,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"exercise","acquired":false,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% vested January 18, 2019 and the remainder vests in equal annual installments over the following three years."}],"balance_after":26250,"derivative":{"exercise_price":50.55,"expiration_date":"2028-01-17","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}},{"id":3576580,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"exercise","acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vested January 18, 2018 and the remainder vests in equal annual installments over the following three years."}],"balance_after":14000,"derivative":{"exercise_price":56.17,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}},{"id":3576579,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"exercise","acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years."}],"balance_after":50000,"derivative":{"exercise_price":37.62,"expiration_date":"2026-05-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}},{"id":3576578,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"tax_withholding","acquired":false,"shares":6228,"price":113.43,"value":706442.04,"ownership":{"direct":true},"balance_after":38828,"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}},{"id":3576577,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"exercise","acquired":true,"shares":8750,"price":50.55,"value":442312.5,"ownership":{"direct":true},"balance_after":45056,"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}},{"id":3576576,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"tax_withholding","acquired":false,"shares":10325,"price":113.43,"value":1171164.75,"ownership":{"direct":true},"balance_after":36306,"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}},{"id":3576575,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"exercise","acquired":true,"shares":14000,"price":56.17,"value":786380.0,"ownership":{"direct":true},"balance_after":46631,"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}},{"id":3576574,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"tax_withholding","acquired":false,"shares":51401,"price":113.42,"value":5829901.42,"ownership":{"direct":true},"balance_after":32631,"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}},{"id":3576573,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":22235,"kind":"person","name":"Faga Daniel","position":1,"cik":"0001673528","reported_name":"Faga Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-03-27T23:18:08.000Z","date":"2019-03-25","kind":"exercise","acquired":true,"shares":80000,"price":37.62,"value":3009600.0,"ownership":{"direct":true},"balance_after":84032,"source":{"system":"sec-edgar","filing":"0000899243-19-009062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673528/000089924319009062/doc4.xml","form_type":"4"}}],"next_cursor":"2019-03-27T23:18:08.000000Z,3576573"}